HomeCompareBIOYF vs BTI

BIOYF vs BTI: Dividend Comparison 2026

BIOYF yields 1.44% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $15.9K in total portfolio value
10 years
BIOYF
BIOYF
● Live price
1.44%
Share price
$10.31
Annual div
$0.15
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.8K
Annual income
$158.64
Full BIOYF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — BIOYF vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOYFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOYF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOYF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOYF
Annual income on $10K today (after 15% tax)
$122.79/yr
After 10yr DRIP, annual income (after tax)
$134.84/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $2,233.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOYF + BTI for your $10,000?

BIOYF: 50%BTI: 50%
100% BTI50/50100% BIOYF
Portfolio after 10yr
$29.7K
Annual income
$1,472.64/yr
Blended yield
4.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

BIOYF
No analyst data
Altman Z
15.8
Piotroski
7/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOYF buys
0
BTI buys
0
No recent congressional trades found for BIOYF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOYFBTI
Forward yield1.44%5.38%
Annual dividend / share$0.15$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$21.8K$37.7K
Annual income after 10y$158.64$2,786.64
Total dividends collected$1.5K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: BIOYF vs BTI ($10,000, DRIP)

YearBIOYF PortfolioBIOYF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$10,844$144.46$11,299$598.92$455.00BTI
2$11,750$146.41$12,794$703.91$1.0KBTI
3$12,721$148.26$14,518$829.07$1.8KBTI
4$13,761$150.01$16,513$978.64$2.8KBTI
5$14,876$151.66$18,827$1,157.84$4.0KBTI
6$16,071$153.22$21,518$1,373.12$5.4KBTI
7$17,350$154.70$24,657$1,632.46$7.3KBTI
8$18,721$156.09$28,329$1,945.74$9.6KBTI
9$20,189$157.40$32,637$2,325.33$12.4KBTI
10$21,761$158.64$37,708$2,786.64$15.9KBTI

BIOYF vs BTI: Complete Analysis 2026

BIOYFStock

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Full BIOYF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this BIOYF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOYF vs SCHDBIOYF vs JEPIBIOYF vs OBIOYF vs KOBIOYF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.